Journal
ATHEROSCLEROSIS SUPPLEMENTS
Volume 13, Issue 1, Pages 1-10Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosissup.2012.06.001
Keywords
Statins; New-onset diabetes; Risk; Diabetogenic; Evidence
Categories
Funding
- Pfizer
- Kowa
Ask authors/readers for more resources
Multiple clinical trials have demonstrated the beneficial effects of statins in lowering levels of low-density lipoprotein and in the prevention of cardiovascular disease. However, although statins have a good safety profile, a debate has been ongoing as to whether use of statins increases risk of new-onset diabetes. Recent large scale meta-analyses of statin trials support the concept of a diabetogenic effect of statins, as do some other small trials assessing changes in glycaemia parameters and insulin levels. However, a definitive mechanism of action has not yet been elucidated. Nevertheless, the level of evidence has been sufficient to lead the FDA to make a change to the labelling of statins. This review assesses the current available evidence and offers a clinical perspective. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available